212 related articles for article (PubMed ID: 15853558)
1. Ziprasidone: a novel psychotropic with unique properties.
Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
[TBL] [Abstract][Full Text] [Related]
2. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
3. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
[TBL] [Abstract][Full Text] [Related]
4. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
5. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
6. Strategies for successful clinical management of schizophrenia with ziprasidone.
Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of ziprasidone: an expanding perspective.
Daniel DG
J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone (Geodon) for schizophrenia.
Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
[No Abstract] [Full Text] [Related]
9. [Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain].
MMW Fortschr Med; 2002 May; Suppl 2():89. PubMed ID: 12070872
[No Abstract] [Full Text] [Related]
10. Maintaining symptom control: review of ziprasidone long-term efficacy data.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
[TBL] [Abstract][Full Text] [Related]
11. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study.
Montejo AL; Rico-Villademoros F;
J Clin Psychopharmacol; 2008 Oct; 28(5):568-70. PubMed ID: 18794656
[No Abstract] [Full Text] [Related]
12. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
13. Ziprasidone-induced oculogyric crisis.
Ramos AE; Shytle RD; Silver AA; Sanberg PR
J Am Acad Child Adolesc Psychiatry; 2003 Sep; 42(9):1013-4. PubMed ID: 12964566
[No Abstract] [Full Text] [Related]
14. Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone.
Frankle WG; Lombardo I; Kegeles LS; Slifstein M; Martin JH; Huang Y; Hwang DR; Reich E; Cangiano C; Gil R; Abi-Dargham A; Laruelle M
J Psychopharmacol; 2011 Jun; 25(6):734-43. PubMed ID: 21109614
[TBL] [Abstract][Full Text] [Related]
15. Brief report on Ziprasidone.
Firoz AH; Rahman AH; Chowdhury WA; Mamun AA
Mymensingh Med J; 2002 Jul; 11(2):129-32. PubMed ID: 12395687
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
[TBL] [Abstract][Full Text] [Related]
17. Drug safety evaluation of ziprasidone.
Citrome L
Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416
[TBL] [Abstract][Full Text] [Related]
18. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
19. Possible ziprasidone-induced mania.
Larson MF; Hauser A
J Am Acad Child Adolesc Psychiatry; 2003 Sep; 42(9):1012; discussion 1012-3. PubMed ID: 12964565
[No Abstract] [Full Text] [Related]
20. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
Ku HL; Su TP; Chou YH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
